| __timestamp | Amicus Therapeutics, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 18372000 |
| Thursday, January 1, 2015 | 76943000 | 15419000 |
| Friday, January 1, 2016 | 104793000 | 23844000 |
| Sunday, January 1, 2017 | 149310000 | 40376000 |
| Monday, January 1, 2018 | 270902000 | 75247000 |
| Tuesday, January 1, 2019 | 286378000 | 89017000 |
| Wednesday, January 1, 2020 | 308443000 | 114764000 |
| Friday, January 1, 2021 | 272049000 | 113864000 |
| Saturday, January 1, 2022 | 276677000 | 130991000 |
| Sunday, January 1, 2023 | 152381000 | 184353000 |
Unlocking the unknown
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amicus consistently outpaced Corcept, with its R&D expenses peaking at nearly 308 million in 2020, a staggering 550% increase from 2014. In contrast, Corcept's R&D spending grew more modestly, reaching its highest point in 2023 with an investment of approximately 184 million, marking a tenfold increase since 2014. This divergence highlights Amicus's aggressive pursuit of new therapies, while Corcept's steady growth reflects a more measured approach. As the biotech sector continues to evolve, these investment patterns may offer insights into each company's future trajectory and potential breakthroughs.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Research and Development Investment: Biogen Inc. vs Corcept Therapeutics Incorporated
Research and Development Investment: United Therapeutics Corporation vs Corcept Therapeutics Incorporated
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Grifols, S.A. and Corcept Therapeutics Incorporated
R&D Insights: How Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV